Compound stypticum

Abstract

A compound medicine for arresting bleeding is characterized in that the compound medicine is a mixture of a batroxobin and an interleukin-11; the clinical dosage of the batroxobin is 0.01-10u and that of IL-11 is 0.06-50mg; the batroxobin is the batroxobin from snake venom of Brazilian spearhead adder, white-eyebrow adder or acutus adder, or the batroxobin from recombinant Brazilian spearhead adder, white-eyebrow adder or acutus adder obtained by genetic engineering; the interleukin-11 is produced by human bone-marrow stromal cells (fibroblasts) and interstitial cells, or the recombinant IL-11 by genetic engineering. The medicine for arresting bleeding can not only ensure the curative effect but also decrease the amount of protease so as to reduce the rate of adverse immune response.

Description

Technical field:

[0001] The invention relates to the technical field of medicine, in particular to a compound hemostatic drug containing two active components of thrombin-like enzyme and IL-11 and a preparation process thereof. Background technique:

[0002] In 1963, the Austrian scholar Von Klobusitzky isolated various coagulation components from the venom of the Brazilian spearhead viper (Bothrops atrox) for the first time, and found that they functioned at different levels of coagulation. The first isolated and purified coagulation component is Batroxobin, which is a serine proteolytic enzyme (Thrombin-LikeEnzyme-like thrombin), also known as Batroxobin (Stocker, K., & Egberg, n., 1973 , Thromb.Diath.Haemorrh.1, 361; Stocker, K., & Barlow, GH., 1976, Method Enzymol.45, 214; Holleman, W.H., & Weiss, L.J., 1976, J.Biol.Chem.251.1663). Batroxobin digests fibrin peptide A in mammalian plasma fibrinogen to convert it into fibrin, so it can cause the aggregation of plasma fibr...